Fact CheckerSign in

NCT06863870Active, not recruiting

Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma

Source: ClinicalTrials.gov · Last updated 7 Mar 2025

Brief summary (registry, in English)

the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
35 (estimated)
First submitted
10 Jan 2025
Start date
24 May 2023
Primary completion date
30 Sept 2024
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diseases
Melanoma
NCT number
NCT06863870

What you commit to

  • Study type: Observational
  • Planned participants: 35
  • From 24 May 2023 to the primary completion date, 30 Sept 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Personal medical history of concomitant other cancer

Who the study is looking for

  • Diagnosis of UM, MM or MUP
  • Diagnosis of metastatic disease
  • Age ≥ 18 years, at the time of the tissue collection

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Coordinator of this site? Confirm its status
BolognaItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.